Preferential efflux by P-glycoprotein, but not MRP1, of compounds containing a free electron donor amine

Biochemical Pharmacology

Volumn 63, Issue 8, 2002, Pages 1471-1479

  Salerno, Milena ^a   Przewloka, Teresa ^b   Fokt, Izabela ^b   Priebe, Waldemar ^b   Garnier Suillerot, Arlette ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Daunorubicin; MRP1; Multidrug resistance; P glycoprotein

Indexed keywords

AMINE; ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN DERIVATIVE; DOXORUBICIN DERIVATIVE; FUNCTIONAL GROUP; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; NITROGEN; UNCLASSIFIED DRUG; WP 744; WP 755; WP 756; WP 757; WP 758; WP 776; WP 785;

ARTICLE; ATOM; CANCER CELL CULTURE; CELL GROWTH; CELL MEMBRANE TRANSPORT; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG UPTAKE; ELECTRON TRANSPORT; GROWTH INHIBITION; HUMAN; HUMAN CELL; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON TRANSPORT; STRUCTURE ACTIVITY RELATION;

AMINES; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; CELL DIVISION; DAUNORUBICIN; HUMANS; K562 CELLS; KINETICS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN;

EID: 0037091106     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)00895-X     Document Type: Article

References (40)

1. Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles
2. Sequential co-expression of the multidrug resistance genes MRP and MDR1 and their products in VP-16 (etoposide)-selected h69 small cell lung cancer cells
3. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
4. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump
5. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line
6. Transport of glutathione conjugates into secretory vesicles is mediated by the multidrug-resistance protein 1
7. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells
8. MOAT-E (ARA) is a full-length MRP cMOAT subfamily transporter expressed in kidney and liver
9. Enhanced transport of anticancer agents and leukotriene C-4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2)
10. Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein
11. Analysis of drug transport kinetics in multidrug-resistant cells: Implications for drug action
12. Structure-activity relationships of multidrug resistance reversers
13. Mechanism of action-governed design of anthracycline antibiotics: "Turn-off/turn-on" approach
14. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity
15. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: Comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines
16. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes
17. P-glycoprotein mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells
18. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells
19. Structure-based design of a new bisintercalating anthracycline antibiotic
20. Determination of the osmotic active drug concentration in the cytoplasm of anthracycline-resistant and-sensitive K562 cells
21. Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells
22. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells
23. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural produce toxins
24. Characterization of vincristine transport by the M-r 190,000 multidrug resistance protein (MRP): Evidence for co-transport with reduced glutathione
25. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1
26. Kinetics of glutathione and daunorubicin efflux from MRP1 overexpressing small cell lung cancer cells
27. The effect of crown ethers, tetraalkylammonium salts, and polyoxyethylene amphiphiles on pirarubicin incorporation in K562 resistant cells
28. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents
29. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone
30. Mobile ionophores are a novel class of P-glycoprotein inhibitors. The effects of ionophores on 4′-O-tetrahydropyranyl-adriamycin incorporation in K562 drug-resistant cells
31. A general pattern for substrate recognition by P-glycoprotein
32. The importance of a nitrogen atom in modulators of multidrug resistance
33. P-glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine
34. Structural analysis of the mouse MDR1a (P-glycoprotein) promoter reveals the basis for the differential transcript heterogeneity in multidrug resistant J774.2 cells
35. Biochemistry of multidrug resistance mediated by the multidrug transporter
36. Functional evidence that transmembrane 12 and the loop between transmembrane 11 and 12 form part of the drug-binding domain in P-glycoprotein encoded by MDR1